Identification and protection of early cardiotoxicity in acute myeloid leukemia patients undergoing transplantation

References

• Brady B, Murphy R. Cancer treatment-related cardiac dysfunction. BMJ Support Palliat Care. 2022 Jul 26. 13(1):53–56. doi:10.1136/spcare-2022-003832
   Web of Science ®Google Scholar
• Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019 Oct 1;4(10):1007–1018. doi:10.1001/jamacardio.2019.2952
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233–270. doi:10.1093/ehjci/jev014
   PubMed Web of Science ®Google Scholar
• Fujiwara SI, Murahashi R, Nakashima H, et al. Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation. Leuk Res. 2022 Oct;121:106951. doi:10.1016/j.leukres.2022.106951
   PubMed Web of Science ®Google Scholar
• Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009 Oct;15(5):392–397. doi:10.1097/MCC.0b013e3283307a4e
   PubMed Web of Science ®Google Scholar
• Getz KD, Sung L, Ky B, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the children's oncology group. J Clin Oncol: Official J Am Soc Clin Oncol. 2019 Jan 1;37(1):12–21. doi:10.1200/jco.18.00313
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912–2919. doi:10.1182/blood-2005-05-2004
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55(3):213–220. doi:10.1016/j.jacc.2009.03.095
   PubMed Web of Science ®Google Scholar
• Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol. 2017 Feb 28;69(8):1043–1056. doi:10.1016/j.jacc.2016.12.012
   PubMed Web of Science ®Google Scholar
• Kang Y, Xu X, Cheng L, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail. 2014 Mar;16(3):300–308. doi:10.1002/ejhf.8
   PubMed Web of Science ®Google Scholar
• Papadopoulos K, Ozden Tok O, Mitrousi K, et al. Myocardial work: methodology and clinical applications. Diagnostics (Basel). 2021 Mar 22;11(3):573. doi:10.3390/diagnostics11030573
   PubMedGoogle Scholar
• Roemer S, Jaglan A, Santos D, et al. The utility of myocardial work in clinical practice. J Am Soc Echocardiogr. 2021 Aug;34(8):807–818. doi:10.1016/j.echo.2021.04.013
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol: Official J Am Soc Clin Oncol. 2017 Mar 10;35(8):893–911. doi: 10.1200/JCO.2016.70.5400.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021 Feb 2;77(4):392–401. doi:10.1016/j.jacc.2020.11.020
   PubMed Web of Science ®Google Scholar
• Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018 May 22;71(20):2281–2290. doi:10.1016/j.jacc.2018.02.049
   PubMed Web of Science ®Google Scholar
• Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159–168. doi:10.1159/000455823.
   PubMed Web of Science ®Google Scholar
• Nabati M, Janbabai G, Baghyari S, et al. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol. 2017 May;69(5):279–285. doi:10.1097/FJC.0000000000000470.
   PubMed Web of Science ®Google Scholar
• Janbabai G, Nabati M, Faghihinia M, et al. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol. 2017 Apr;17(2):130–139. doi:10.1007/s12012-016-9365-z
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 ( 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1;37(21):1671–1680. doi:10.1093/eurheartj/ehw022
   PubMed Web of Science ®Google Scholar
• Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international CardioOncology society-one trial. Eur J Cancer. 2018 May;94:126–137. doi:10.1016/j.ejca.2018.02.005
   PubMed Web of Science ®Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (Prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013 Jun 11;61(23):2355–2362. doi:10.1016/j.jacc.2013.02.072
   PubMed Web of Science ®Google Scholar
• Docherty KF, Vaduganathan M, Solomon SD, et al. Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800–810. doi:10.1016/j.jchf.2020.06.020
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep;15(9):1062–1073. doi:10.1093/eurjhf/hft052
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 Oct 24;381(17):1609–1620. doi:10.1056/NEJMoa1908655
   PubMed Web of Science ®Google Scholar
• De Vecchis R, Paccone A, Di Maio M. Sacubitril/valsartan therapy for 14 months induces a marked improvement of global longitudinal strain in patients with chronic heart failure: a retrospective cohort study. Cardiol Res. 2019 Oct;10(5):293–302. doi:10.14740/cr910
   PubMed Web of Science ®Google Scholar
• Mirić D, Baković D, Eterović D, et al. Left-ventricular function after 3 months of sacubitril-valsartan in acute decompensated heart failure. J Cardiovasc Transl Res. 2021 Apr;14(2):290–298. doi:10.1007/s12265-020-10041-4
   PubMed Web of Science ®Google Scholar
• Gregorietti V, Fernandez TL, Costa D, et al. Use of sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020 Nov 5;6(1):24. doi:10.1186/s40959-020-00078-4
   PubMedGoogle Scholar
• Martin-Garcia A, Lopez-Fernandez T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020 Apr;7(2):763–767. doi:10.1002/ehf2.12627
   PubMed Web of Science ®Google Scholar